Increasing Adoption of NGS in Various Research and Diagnostics Fields
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is anticipated to reach $2,370.7 million by 2027, witnessing a CAGR of 17.56% during the forecast period 2022-2027. The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, growing prevalence of non-communicable disorders, and advancement in the performance of NGS platforms.
Market Lifecycle Stage
The Asia-Pacific and Middle East NGS market is highly consolidated. This market still holds significant potential for growth as technological developments in NGS platforms and initiatives to integrate genomics in healthcare are ongoing.
The opportunity for growth of the Asia-Pacific and Middle East NGS market lies in development of economical and portable technologies.
Impact of COVID-19
Next-generation sequencing (NGS)-based products are widely employed in research and diagnosis of diseases such as cancer, as well as providing cancer patients with appropriate and individualized therapy. Because the market is dominated primarily by manufacturers of next-generation sequencing instruments, kits, and assays, as well as service providers that provide gene panels and testing services using next-generation sequencing for oncology, the pandemic had a negative impact on the market's revenue growth.
However, during the COVID-19 pandemic, next-generation sequencing (NGS) and analytics were increasingly employed for sequencing the SARS-CoV-2 virus, to track its mutations, and manage population health. For example, in October 2022, Kyrgyzstan began building next-generation sequencing capabilities for SARS-CoV-2. Leaders in this sequencing industry have predicted a greater push toward local manufacturing rather than its dependency on import activities. The pandemic revealed cracks in the supply chain, prompting Asia-Pacific and Middle East countries to strengthen local production of medicines where possible.
Market Segmentation
Segmentation 1: by Offerings
- Consumables
- Equipment
- Services
The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment.
Segmentation 2: by Platform
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific BioSciences of California, Inc.
- Oxford Nanopore Technologies plc.
- Other Companies
The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc.
Segmentation 3: by Throughput
- High-Throughput
- Medium-Throughput
- Low-Throughput
The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment.
Segmentation 4: by Technology Type
- Sequencing by Synthesis
- Ion Torrent Semiconductor Sequencing
- Single Molecule Real-Time Sequencing
- Nanopore Sequencing Technology
- Other Technologies
The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.
Segmentation 5: by Application
- Clinical Diagnostics
- Translational Research
- Other Applications
The Asia-Pacific NGS market (by application) is expected to be dominated by the translational research segment.
Segmentation 6: by End User
- Academic and Research Institutes
- Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
- Other End Users
The Asia-Pacific NGS market (by end-user) is expected to be dominated by the academic and research institutes segment.
Segmentation 7: by Country
- Asia-Pacific (Japan, India, South Korea, Australia, Singapore, New Zealand, Rest-of-Asia-Pacific)
- Middle East (U.A.E., K.S.A., Egypt, Israel, Rest-of-Middle East)
The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E.
Recent Developments in the Asia-Pacific and Middle East NGS Market
- In October 2022, the company introduced Revio and Onso - new sequencing systems; Revio is a long-read sequencing system that allows the sequencing of up to 1,300 human whole genomes per year, while Onso is a benchtop short-read DNA sequencing platform. The system enables scaling of the use of PacBio’s HiFi sequencing technology for large studies in human genetics, cancer research, and agricultural genomics, among others.
- In September 2022, Illumina, Inc. introduced Illumina Complete Long-Reads (INFINITY) for human whole-genome sequencing (WGS). This resulted in a high-performance, streamlined, integrated method. Furthermore, the platform showed compatibility with all NovaSeq systems for the synthesis of thousands of long-read genomes every year.
- In September 2022, Illumina, Inc. introduced the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, the NovaSeq 6000 Dx. The NovaSeq 6000 Dx is a versatile platform that provides the greatest levels of compliance while also delivering useful insights for patient care.
- In August 2022, Illumina, Inc. teamed with Minderoo Foundation and contributed $27.8 million to improve genetic knowledge of marine systems. This innovative collaboration used Illumina's NextSeq 2000 sequencing system to assess and understand marine life in seas.
- In April 2022, the company expanded its relationship with Genomics England, which is evaluating the therapeutic and scientific uses of full genomic analysis of cancer tumors using nanopore technology in an ongoing project.
- In March 2022, the company introduced CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer. This sequencer is fully automated, producing data in a single day.
- In January 2022, Pacific Biosciences of California, Inc. collaborated with Genomics England, a company created to deliver the 100,000 Genomes Project to study PacBio's technology for the identification of genetic variants in cancer and rare disease cases. As part of the collaboration, Genomics England will re-sequence biobank samples collected during the 100,000 Genomes Project using Pacific Biosciences of California, Inc.'s long-read sequencing technology to identify additional genomic variants that are not readily accessible by short-read sequencing technologies.
Demand - Drivers and Limitations
The following are the drivers for the Asia-Pacific and Middle East NGS market:
- Increasing Adoption of NGS in Various Research and Diagnostics Fields
- Growing Prevalence of Non-Communicable Diseases
- Advancement in the Performance of NGS Platforms
The market is expected to face some limitations as well due to the following challenges:
- Dearth of Skilled Professionals in Middle East Countries
- High Cost of Installation and Maintenance of the Equipment
- Reimbursement and Regulatory Policies of NGS
How can this report add value to an organization?
Type: The Asia-Pacific and Middle East NGS market has been extensively segmented on the basis of various categories such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., over 70% of the total developments in the global Asia-Pacific and Middle East NGS market.
Competitive Strategy: The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services.
Key Market Players and Competition Synopsis
The Asia-Pacific an Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share.
Key Companies Profiled
- BGI Group
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc.
Table of Contents
1 Markets
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 NGS: Overview
1.2.2 Asia-Pacific and Middle East NGS Market: Overview
1.2.3 Emerging Applications of NGS in the Asia-Pacific and Middle East NGS Market
1.2.4 COVID-19 Impact on Asia-Pacific and Middle East NGS Market
1.2.5 Supply Chain Analysis
1.2.5.1 Key Entities in Supply Chain
1.3 Industry Analysis
1.3.1 Legal Requirements and Framework in Asia-Pacific
1.3.2 Legal Requirements and Framework in the Middle East
1.3.3 Genome Projects in Asia-Pacific and the Middle East
1.4 Market Dynamics
1.4.1 Impact Analysis
1.4.2 Market Drivers
1.4.2.1 Increasing Adoption of NGS in Various Research and Diagnostics Fields
1.4.2.2 Growing Prevalence of Non-Communicable Diseases
1.4.2.3 Advancement in the Performance of NGS Platforms
1.4.3 Market Restraints
1.4.3.1 Dearth of Skilled Professionals in Middle East Countries
1.4.3.2 High Cost of Installation and Maintenance of the Equipment
1.4.3.3 Reimbursement and Regulatory Policies of NGS
1.4.4 Market Opportunities
1.4.4.1 Development of Economical and Portable Technologies
2 Asia-Pacific and Middle East NGS Market (by Offering)
2.1 Overview
2.2 Consumables
2.2.1 Asia-Pacific
2.2.2 Middle East
2.3 Equipment
2.3.1 Asia-Pacific
2.3.2 Middle East
2.4 Services
2.4.1 Asia-Pacific
2.4.2 Middle East
3 Asia-Pacific and Middle East NGS Market (by Platform)
3.1 Overview
3.1.1 Asia-Pacific
3.1.2 Middle East
3.2 Illumina, Inc.
3.2.1 iSeq
3.2.1.1 Asia-Pacific
3.2.1.2 Middle East
3.2.2 MiniSeq
3.2.2.1 Asia-Pacific
3.2.2.2 Middle East
3.2.3 MiSeq
3.2.3.1 Asia-Pacific
3.2.3.2 Middle East
3.2.4 NextSeq
3.2.4.1 Asia-Pacific
3.2.4.2 Middle East
3.2.5 NovaSeq
3.2.5.1 Asia-Pacific
3.2.5.2 Middle East
3.3 Thermo Fisher Scientific Inc.
3.3.1 Ion PGM
3.3.1.1 Asia-Pacific
3.3.1.2 Middle East
3.3.2 Ion GeneStudio S5
3.3.2.1 Asia-Pacific
3.3.2.2 Middle East
3.3.3 Ion Proton
3.3.3.1 Asia-Pacific
3.3.3.2 Middle East
3.3.4 Ion Torrent Genexus
3.3.4.1 Asia-Pacific
3.3.4.2 Middle East
3.4 Pacific Biosciences of California, Inc.
3.4.1 Sequel II/IIe
3.4.1.1 Asia-Pacific
3.4.1.2 Middle East
3.5 Oxford Nanopore Technologies plc.
3.5.1 MinION
3.5.1.1 Asia-Pacific
3.5.1.2 Middle East
3.5.2 GridION
3.5.2.1 Asia-Pacific
3.5.2.2 Middle East
3.5.3 PromethION
3.5.3.1 Asia-Pacific
3.5.3.2 Middle East
3.6 Other Companies
3.6.1 Asia-Pacific
3.6.2 Middle East
4 Asia-Pacific and Middle East NGS Market (by Throughput)
4.1 Overview
4.1.1 Asia-Pacific
4.1.2 Middle East
4.2 High-Throughput
4.2.1 Asia-Pacific
4.2.2 Middle East
4.3 Medium-Throughput
4.3.1 Asia-Pacific
4.3.2 Middle East
4.4 Low-Throughput
4.4.1 Asia-Pacific
4.4.2 Middle East
5 Asia-Pacific NGS Market (by Technology Type)
5.1 Overview
5.2 Sequencing by Synthesis
5.3 Ion Torrent Semiconductor Sequencing
5.4 Single Molecule Real-Time Sequencing
5.5 Nanopore Sequencing Technology
5.6 Other Technologies
6 Asia-Pacific NGS Market (by Application)
6.1 Overview
6.2 Clinical Diagnostics
6.2.1 Oncology
6.2.2 Infectious Diseases
6.2.3 Reproductive Genetics
6.2.4 Other Diagnostics Applications
6.3 Translational Research
6.3.1 Clinical Research
6.3.2 Agricultural Research
6.3.3 Other Translational Research
6.4 Other Applications
7 Asia-Pacific NGS Market (by End User)
7.1 Overview
7.2 Academic and Research Institutes
7.3 Clinical Laboratories
7.4 Pharmaceutical and Biotechnology Companies
7.5 Other End Users
8 Asia-Pacific NGS Market (by Country)
8.1 Overview
8.2 Key Distributors
8.3 Japan
8.4 India
8.5 South Korea
8.6 Australia
8.7 Singapore
8.8 New Zealand
8.9 Rest-of-Asia-Pacific
9 Middle East NGS Market (by Country)
9.1 Overview
9.2 Key Distributors
9.3 U.A.E.
9.4 K.S.A.
9.5 Egypt
9.6 Israel
9.7 Rest-of-Middle East
10 Markets - Competitive Benchmarking & Company Profiles
10.1 Competitive Landscape
10.1.1 Overview
10.1.2 Corporate Strategies
10.1.2.1 Mergers and Acquisitions
10.1.2.2 Synergistic Activities
10.1.2.3 Business Expansions and Funding
10.1.3 Business Strategies
10.1.3.1 Product Launches/Upgradations/Approvals
10.2 Market Share Analysis
10.3 Growth-Share Analysis for Asia-Pacific NGS Market (by End User)
10.4 Growth-Share Analysis for Middle East NGS Market (by Throughput)
10.5 Company Profiles
10.5.1 BGI Group
10.5.1.1 Company Overview
10.5.1.2 Role of BGI Group in the Asia-Pacific and Middle East NGS Market
10.5.1.3 Overall Product Portfolio
10.5.1.4 Key Developments
10.5.1.5 Analyst Perception
10.5.2 Illumina, Inc.
10.5.2.1 Company Overview
10.5.2.2 Role of Illumina, Inc. in the Asia-Pacific and Middle East NGS Market
10.5.2.3 Overall Product Portfolio
10.5.2.4 Recent Developments
10.5.2.5 Financials
10.5.2.6 Analyst Perception
10.5.3 Thermo Fisher Scientific Inc.
10.5.3.1 Company Overview
10.5.3.2 Role of Thermo Fisher Scientific Inc. in the Asia-Pacific and Middle East NGS Market
10.5.3.3 Overall Product Portfolio
10.5.3.4 Recent Developments
10.5.3.5 Financials
10.5.3.6 Analyst Perception
10.5.4 Pacific Biosciences of California, Inc.
10.5.4.1 Company Overview
10.5.4.2 Role of Pacific Biosciences of California, Inc. in the Asia-Pacific and Middle East NGS Market
10.5.4.3 Overall Product Portfolio
10.5.4.4 Recent Developments
10.5.4.5 Financials
10.5.4.6 Analyst Perception
10.5.5 Oxford Nanopore Technologies plc.
10.5.5.1 Company Overview
10.5.5.2 Role of Oxford Nanopore Technologies plc. in the Asia-Pacific and Middle East NGS Market
10.5.5.3 Overall Product Portfolio
10.5.5.4 Recent Developments
10.5.5.5 Financials
10.5.5.6 Analyst Perception
List of Figures
Figure 1: Asia-Pacific and Middle East NGS Market, Impact Analysis
Figure 2: Growth-Share Analysis for Middle East NGS Market (by Key Players), 2021
Figure 3: Asia-Pacific and Middle East NGS Market (by Region), Share (%), 2021 and 2027
Figure 4: Asia-Pacific and Middle East NGS Market Segmentation
Figure 5: Asia-Pacific and Middle East NGS Market Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Asia-Pacific and Middle East NGS Market, NGS Workflow
Figure 10: Asia-Pacific NGS Market, $Million, 2021-2027
Figure 11: Middle East NGS Market, $Million, 2021-2027
Figure 12: Asia-Pacific and Middle East NGS Market, NGS Applications
Figure 13: Asia-Pacific and Middle East NGS Market, Supply Chain Analysis
Figure 14: Asia-Pacific and Middle East NGS Market, Impact Analysis
Figure 15: Asia-Pacific and Middle East NGS Market, Applications of NGS in Various Research and Diagnostics Fields
Figure 16: Asia-Pacific and Middle East NGS Market, Comparison of NGS Technologies
Figure 17: Asia-Pacific and Middle East NGS Market, Major Factors Influencing Adoption of NGS in Various Research and Diagnostics Fields
Figure 18: Asia-Pacific and Middle East NGS Market, Non-Communicable Diseases (NCDs) Mortality Rate (by Country), 2020 and 2022
Figure 19: Asia-Pacific and Middle East NGS Market, Different Generations of Sequencing
Figure 20: Asia-Pacific and Middle East NGS Market, Percentage of People with Shortage of Skills in the Middle East
Figure 21: Asia-Pacific NGS Market (by Offering), Share (%), 2021 and 2027
Figure 22: Middle East NGS Market (by Offering), Share (%), 2021 and 2027
Figure 23: Asia-Pacific NGS Market (Consumables), $Million, 2021-2027
Figure 24: Middle East NGS Market (Consumables), $Million, 2021-2027
Figure 25: Asia-Pacific NGS Market (Equipment), $Million, 2021-2027
Figure 26: Middle East NGS Market (Equipment), $Million, 2021-2027
Figure 27: Asia-Pacific NGS Market (Services), $Million, 2021-2027
Figure 28: Middle East NGS Market (Services), $Million, 2021-2027
Figure 29: Asia-Pacific NGS Market (by Platform), Share (%), 2021 and 2027
Figure 30: Asia-Pacific NGS Market (by Platform), Units, 2021 and 2027
Figure 31: Middle East NGS Market (by Platform), Share (%), 2021 and 2027
Figure 32: Middle East NGS Market (by Platform), Units, Share (%), 2021 and 2027
Figure 33: Asia-Pacific NGS Market (Illumina, Inc.), $Million, 2021-2027
Figure 34: Asia-Pacific NGS Market (Illumina, Inc.), Units, 2021-2027
Figure 35: Illumina, Inc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 36: Middle East NGS Market (Illumina, Inc.), $Million, 2021-2027
Figure 37: Middle East NGS Market (Illumina, Inc.), Units, 2021-2027
Figure 38: Illumina, Inc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 39: Asia-Pacific NGS Market (iSeq), $Million, 021-2027
Figure 40: Asia-Pacific NGS Market (iSeq), Units, 2021-2027
Figure 41: Middle East NGS Market (iSeq), $Million, 2021-2027
Figure 42: Middle East NGS Market (iSeq), Units, 2021-2027
Figure 43: Asia-Pacific NGS Market (MiniSeq), $Million, 2021-2027
Figure 44: Asia-Pacific NGS Market (MiniSeq), Units, 2021-2027
Figure 45: Middle East NGS Market (MiniSeq), $Million, 2021-2027
Figure 46: Middle East NGS Market (MiniSeq), Units, 2021-2027
Figure 47: Asia-Pacific NGS Market (MiSeq), $Million, 2021-2027
Figure 48: Asia-Pacific NGS Market (MiSeq), Units, 2021-2027
Figure 49: Middle East NGS Market (MiSeq), $Million, 2021-2027
Figure 50: Middle East NGS Market (MiSeq), Units, 2021-2027
Figure 51: Asia-Pacific NGS Market (NextSeq), $Million, 2021-2027
Figure 52: Asia-Pacific NGS Market (NextSeq), Units, 2021-2027
Figure 53: Middle East NGS Market (NextSeq), $Million, 2021-2027
Figure 54: Middle East NGS Market (NextSeq), Units, 2021-2027
Figure 55: Asia-Pacific NGS Market (NovaSeq), $Million, 2021-2027
Figure 56: Asia-Pacific NGS Market (NovaSeq), Units, 2021-2027
Figure 57: Middle East NGS Market (NovaSeq), $Million, 2021-2027
Figure 58: Middle East NGS Market (NovaSeq), Units, 2021-2027
Figure 59: Asia-Pacific NGS Market (Thermo Fisher Scientific Inc.), $Million, 2021-2027
Figure 60: Asia-Pacific NGS Market (Thermo Fisher Scientific Inc.), Units, 2021-2027
Figure 61: Thermo Fisher Scientific Inc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 62: Middle East NGS Market (Thermo Fisher Scientific Inc.), $Million, 2021-2027
Figure 63: Middle East NGS Market (Thermo Fisher Scientific Inc.), Units, 2021-2027
Figure 64: Thermo Fisher Scientific Inc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 65: Asia-Pacific NGS Market (Ion PGM), $Million, 2021-2027
Figure 66: Asia-Pacific NGS Market (Ion PGM), Units, 2021-2027
Figure 67: Middle East NGS Market (Ion PGM), $Million, 2021-2027
Figure 68: Middle East NGS Market (Ion PGM), Units, 2021-2027
Figure 69: Asia-Pacific NGS Market (Ion GeneStudio S5), $Million, 2021-2027
Figure 70: Asia-Pacific NGS Market (Ion GeneStudio S5), Units, 2021-2027
Figure 71: Middle East NGS Market (Ion GeneStudio S5), $Million, 2021-2027
Figure 72: Middle East NGS Market (Ion GeneStudio S5), Units, 2021-2027
Figure 73: Asia-Pacific NGS Market (Ion Proton), $Million, 2021-2027
Figure 74: Asia-Pacific NGS Market (Ion Proton), Units, 2021-2027
Figure 75: Middle East NGS Market (Ion Proton), $Million, 2021-2027
Figure 76: Middle East NGS Market (Ion Proton), Units, 2021-2027
Figure 77: Asia-Pacific NGS Market (Ion Torrent Genexus), $Million, 2021-2027
Figure 78: Asia-Pacific NGS Market (Ion Torrent Genexus), Units, 2021-2027
Figure 79: Middle East NGS Market (Ion Torrent Genexus), $Million, 2021-2027
Figure 80: Middle East NGS Market (Ion Torrent Genexus), Units, 2021-2027
Figure 81: Asia-Pacific NGS Market (Pacific Biosciences of California, Inc.), $Million, 2021-2027
Figure 82: Asia-Pacific NGS Market (Pacific Biosciences of California, Inc.), Units, 2021-2027
Figure 83: Pacific Biosciences of California, Inc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 84: Middle East NGS Market (Pacific Biosciences of California, Inc.), $Million, 2021-2027
Figure 85: Middle East NGS Market (Pacific Biosciences of California, Inc.), Units, 2021-2027
Figure 86: Asia-Pacific NGS Market (Sequel II/IIe), $Million, 2021-2027
Figure 87: Asia-Pacific NGS Market (Sequel II/IIe), Units, 2021-2027
Figure 88: Middle East NGS Market (Sequel II/IIe), $Million, 2021-2027
Figure 89: Middle East NGS Market (Sequel II/IIe), Units, 2021-2027
Figure 90: Asia-Pacific NGS Market (Oxford Nanopore Technologies plc.), $Million, 2021-2027
Figure 91: Asia-Pacific NGS Market (Oxford Nanopore Technologies plc.), Units, 2021-2027
Figure 92: Oxford Nanopore Technologies plc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 93: Middle East NGS Market (Oxford Nanopore Technologies plc.), $Million, 2021-2027
Figure 94: Middle East NGS Market (Oxford Nanopore Technologies plc.), Units, 2021-2027
Figure 95: Oxford Nanopore Technologies plc. (by Equipment), Units, Share (%), 2021 and 2027
Figure 96: Asia-Pacific NGS Market (MinION), $Million, 2021-2027
Figure 97: Asia-Pacific NGS Market (MinION), Units, 2021-2027
Figure 98: Middle East NGS Market (MinION), $Million, 2021-2027
Figure 99: Middle East NGS Market (MinION), Units, 2021-2027
Figure 100: Asia-Pacific NGS Market (GridION), $Million, 2021-2027
Figure 101: Asia-Pacific NGS Market (GridION), Units, 2021-2027
Figure 102: Middle East NGS Market (GridION), $Million, 2021-2027
Figure 103: Middle East NGS Market (GridION), Units, 2021-2027
Figure 104: Asia-Pacific NGS Market (PromethION), $Million, 2021-2027
Figure 105: Asia-Pacific NGS Market (PromethION), Units, 2021-2027
Figure 106: Middle East NGS Market (PromethION), $Million, 2021-2027
Figure 107: Middle East NGS Market (PromethION), Units, 2021-2027
Figure 108: Asia-Pacific NGS Market (Other Companies), Units, 2021-2027
Figure 109: Middle East NGS Market (Other Companies), $Million, 2021-2027
Figure 110: Middle East NGS Market (Other Companies), Units, 2021-2027
Figure 111: Asia-Pacific and Middle East NGS Market (by Throughput)
Figure 112: Asia-Pacific NGS Market (by Throughput), Share (%), 2021 and 2027
Figure 113: Middle East NGS Market (by Throughput), Share (%), 2021 and 2027
Figure 114: Asia-Pacific NGS Market (High-Throughput), $Million, 2021-2027
Figure 115: Asia-Pacific NGS Market (High-Throughput, by Equipment), Units, 2021-2027
Figure 116: Asia-Pacific NGS Market (High-Throughput, by Offering), $Million, 2021-2027
Figure 117: Middle East NGS Market (High-Throughput), $Million, 2021-2027
Figure 118: Middle East NGS Market (High-Throughput, by Equipment), Units, 2021-2027
Figure 119: Middle East NGS Market (High-Throughput, by Offering), $Million, 2021-2027
Figure 120: Asia-Pacific NGS Market (Medium-Throughput), $Million, 2021-2027
Figure 121: Asia-Pacific NGS Market (Medium-Throughput, by Equipment), Units, 2021-2027
Figure 122: Asia-Pacific NGS Market (Medium-Throughput, by Offering), $Million, 2021-2027
Figure 123: Middle East NGS Market (Medium-Throughput), $Million, 2021-2027
Figure 124: Middle East NGS Market (Medium-Throughput, by Equipment), Units, 2021-2027
Figure 125: Middle East NGS Market (Medium-Throughput, by Offering), $Million, 2021-2027
Figure 126: Asia-Pacific NGS Market (Low-Throughput), $Million, 2021-2027
Figure 127: Asia-Pacific NGS Market (Low-Throughput, by Equipment), Units, 2021-2027
Figure 128: Asia-Pacific NGS Market (Low-Throughput, by Offering), $Million, 2021-2027
Figure 129: Middle East NGS Market (Low-Throughput), $Million, 2021-2027
Figure 130: Middle East NGS Market (Low-Throughput, by Equipment), Units, 2021-2027
Figure 131: Middle East NGS Market (Low-Throughput, by Offering), $Million, 2021-2027
Figure 132: Asia-Pacific NGS Market (Technology Type), $Million, 2021-2027
Figure 133: Asia-Pacific NGS Market (by Technology Type), Share (%), 2021 and 2027
Figure 134: Asia-Pacific NGS Market (Sequencing by Synthesis), $Million, 2021-2027
Figure 135: Asia-Pacific NGS Market (Ion Torrent Semiconductor Sequencing), $Million, 2021-2027
Figure 136: Asia-Pacific NGS Market (Single Molecule Real-Time Sequencing), $Million, 2021-2027
Figure 137: Asia-Pacific NGS Market (Nanopore Sequencing Technology), $Million, 2021-2027
Figure 138: Asia-Pacific NGS Market (Other Technologies), $Million, 2021 and 2027
Figure 139: Asia-Pacific NGS Market (Application), $Million, 2021-2027
Figure 140: Asia-Pacific NGS Market (by Application), Share (%), 2021 and 2027
Figure 141: Use of NGS in Clinical Diagnostics
Figure 142: Asia-Pacific NGS Market (Clinical Diagnostics), $Million, 2021-2027
Figure 143: Asia-Pacific NGS Market (by Clinical Diagnostics), Share (%), 2021 and 2027
Figure 144: Applications of NGS in Oncology
Figure 145: Asia-Pacific NGS Market (Oncology), $Million, 2021-2027
Figure 146: Role of NGS in Infectious Diseases
Figure 147: Asia-Pacific NGS Market (Infectious Diseases), $Million, 2021-2027
Figure 148: Role of NGS in Reproductive Genetics
Figure 149: Asia-Pacific NGS Market (Reproductive Genetics), $Million, 2021-2027
Figure 150: Asia-Pacific NGS Market (Other Diagnostics Applications), $Million, 2021-2027
Figure 151: Asia-Pacific NGS Market (Translational Research), $Million, 2021-2027
Figure 152: Asia-Pacific NGS Market (by Translational Research), Share (%), 2021 and 2027
Figure 153: Asia-Pacific NGS Market (Clinical Research), $Million, 2021-2027
Figure 154: Asia-Pacific NGS Market (by Clinical Research), $Million, 2021-2027
Figure 155: Asia-Pacific NGS Market (by Clinical Research), Share (%), 2021 and 2027
Figure 156: Asia-Pacific NGS Market (Agricultural Research), $Million, 2021-2027
Figure 157: Asia-Pacific NGS Market (Other Translational Research), $Million, 2021-2027
Figure 158: Asia-Pacific NGS Market (Other Applications), $Million, 2021-2027
Figure 159: Asia-Pacific NGS Market (by End User), Share (%), 2021 and 2027
Figure 160: Asia-Pacific NGS Market (Academic and Research Institutes), $Million, 2021-2027
Figure 161: Asia-Pacific NGS Market (Academic and Research Institutes, by Offering), $Million, 2021-2027
Figure 162: Asia-Pacific NGS Market (Clinical Laboratories), $Million, 2021-2027
Figure 163: Asia-Pacific NGS Market (Clinical Laboratories, by Offering), $Million, 2021-2027
Figure 164: Asia-Pacific NGS Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2027
Figure 165: Asia-Pacific NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2021-2027
Figure 166: Asia-Pacific NGS Market (Other End Users), $Million, 2021-2027
Figure 167: Asia-Pacific NGS Market (Other End Users, by Offering), $Million, 2021-2027
Figure 168: Asia-Pacific NGS Market (by Country)
Figure 169: Japan NGS Market (by Offering), $Million, 2021-2027
Figure 170: Japan NGS Market (Equipment), Units, 2021-2027
Figure 171: Japan NGS Market (by Platform), $Million, 2021-2027
Figure 172: India NGS Market (by Offering), $Million, 2021-2027
Figure 173: India NGS Market (Equipment), Units, 2021-2027
Figure 174: India NGS Market (by Platform), $Million, 2021
Figure 175: South Korea NGS Market (by Offering), $Million, 2021-2027
Figure 176: South Korea NGS Market (Equipment), Units, 2021-2027
Figure 177: South Korea NGS Market (by Platform), $Million, 2021-2027
Figure 178: Australia NGS Market (by Offering), $Million, 2021-2027
Figure 179: Australia NGS Market (Equipment), Units, 2021-2027
Figure 180: Australia NGS Market (by Platform), $Million, 2021-2027
Figure 181: Singapore NGS Market (by Offering), $Million, 2021-2027
Figure 182: Singapore NGS Market (Equipment), Units, 2021-2027
Figure 183: Singapore NGS Market (by Platform), $Million, 2021-2027
Figure 184: New Zealand NGS Market (by Offering), $Million, 2021-2027
Figure 185: New Zealand NGS Market (Equipment), Units, 2021-2027
Figure 186: New Zealand NGS Market (by Platform), $Million, 2021
Figure 187: Rest-of-Asia-Pacific NGS Market (by Offering), $Million, 2021-2027
Figure 188: Rest-of-Asia-Pacific NGS Market (Equipment), Units, 2021-2027
Figure 189: Rest-of-Asia-Pacific NGS Market (by Platform), $Million, 2021-2027
Figure 190: Middle East NGS Market (by Country)
Figure 191: U.A.E. NGS Market (by Offering), $Million, 2021-2027
Figure 192: U.A.E. NGS Market (Equipment), Units, 2021-2027
Figure 193: U.A.E NGS Market (by Platform), $Million, 2021-2027
Figure 194: K.S.A. NGS Market (by Offering), $Million, 2021-2027
Figure 195: K.S.A. NGS Market (Equipment), Units, 2021-2027
Figure 196: KSA NGS Market (by Platform), $Million, 2021-2027
Figure 197: Egypt NGS Market (by Offering), $Million, 2021-2027
Figure 198: Egypt NGS Market (Equipment), Units, 2021-2027
Figure 199: Egypt NGS Market (by Platform), $Million, 2021-2027
Figure 200: Israel NGS Market (by Offering), $Million, 2021-2027
Figure 201: Israel NGS Market (Equipment), Units, 2021-2027
Figure 202: Israel NGS Market (by Platform), $Million, 2021-2027
Figure 203: Rest-of-Middle East NGS Market (by Offering), $Million, 2021-2027
Figure 204: Rest-of-Middle East NGS Market (Equipment), Units, 2021-2027
Figure 205: Rest-of-Middle East NGS Market (by Platform), $Million, 2021-2027
Figure 206: Share of Key Developments, January 2019-January 2023
Figure 207: Share of Synergistic Activities (by Company), January 2019-January 2023
Figure 208: Share of Business Expansions and Funding Activities (by Company), January 2019-January 2023
Figure 209: Share of Product Launches/Upgradations/Approvals (by Company), January 2019-January 2023
Figure 210: Market Share Analysis for Asia-Pacific and Middle East NGS Market, 2021 and 2027
Figure 211: Growth-Share Analysis for Asia-Pacific NGS Market (by End User), 2021
Figure 212: Growth-Share Analysis for Middle East NGS Market (by Throughput), 2021
Figure 213: Share of Company Profiled
Figure 214: BGI Group: Overall Product Portfolio
Figure 215: Illumina, Inc.: Overall Product Portfolio
Figure 216: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 217: Illumina, Inc.: Segment Revenues, $Million, 2019-2021
Figure 218: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 219: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 220: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 221: Thermo Fisher Scientific Inc.: Segment Revenues, $Million, 2019-2021
Figure 222: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 223: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 224: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2019-2021
Figure 225: Pacific Biosciences of California, Inc.: Segment Revenue, $Million, 2019-2021
Figure 226: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 227: Oxford Nanopore Technologies plc.: Overall Product Portfolio
Figure 228: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2019-2021
Figure 229: Oxford Nanopore Technologies plc.: Segment Revenue, $Million, 2019-2021
Figure 230: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Asia-Pacific and Middle East NGS Market, Yearly Key Developments Analysis, January 2019-January 2023
Table 2: Key Questions Answered in the Report
Table 3: Legal Requirements and Framework in Asia-Pacific (by Country)
Table 4: Legal Requirements and Framework in the Middle East (by Country)
Table 5: Genome Projects (by Country)
Table 6: Major Sequencers in NGS Market, Performance Comparative Analysis
Table 7: Asia-Pacific and Middle East NGS Market, Maintenance Cost of NGS Equipment
Table 8: Asia-Pacific and Middle East NGS Market, Examples of Portable Sequencers
Table 9: Some Examples of Sequencing by Synthesis Technology
Table 10: Some Examples of Ion Torrent Semiconductor Sequencing Technology
Table 11: Some Examples of Single Molecule Real-Time Sequencing Technology
Table 12: Some Examples of Nanopore Sequencing Technology
Table 13: Some of the Key Distributors in Asia-Pacific (by Company)
Table 14: Some of the Key Distributors in the Middle East (by Company)
Companies Mentioned
- BGI Group
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 217 |
| Published | April 2023 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 1055.6 Million |
| Forecasted Market Value ( USD | $ 2370.7 Million |
| Compound Annual Growth Rate | 17.6% |
| Regions Covered | Asia Pacific, Middle East |
| No. of Companies Mentioned | 5 |
